90%Confidence
0Views
FDASource
2026-03-28Date
Summary
Harbin Jixianglong's Semaglutide recall due to validation failures highlights significant regulatory risks in the compounding pharmacy supply chain, particularly for high-demand weight loss medications. This creates potential opportunities for FDA-approved semaglutide manufacturers to capture market share.
Actionable: Immediately discontinue use of affected semaglutide lots and source only from FDA-approved manufacturers with validated quality systems.
AI Confidence: 90%
Data Points
firmHarbin Jixianglong Biotech Co., Ltd.
classificationClass II
statusOngoing
distributionNationwide within the United States
productSemaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-1
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now